

21 August 2009

2009/10 Multi-product Tender

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply;
- The draft process and terms and conditions for the Invitation to Tender 2009/10; and
- Commercial Proposals as an alternative to tendering.

PHARMAC welcomes all feedback.

**ALTERNATIVE COMMERCIAL PROPOSAL RESPONSES DUE BY
5 PM, FRIDAY 25 SEPTEMBER 2009**

**AND ALL OTHER CONSULTATION RESPONSES BY
5 PM, FRIDAY 2 OCTOBER 2009**

Feedback should be provided by submitting an email, fax or letter to:

Yvonne Chen
Tender Analyst
PHARMAC
PO Box 10-254
Wellington 6143

Email: yvonne.chen@pharmac.govt.nz

Fax: (04) 460 4995
DDI: (04) 916 7556

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposed 2009/10 multi-product tender

In general, the proposed Tender process would be similar to the 2008/09 Tender. In addition to Alternative Commercial Proposals that are discussed later, we seek comments on the approach outlined in the following pages, in particular on:

- The proposed process;
- The proposed timetable;
- An indication of any pharmaceuticals, whether or not included in Schedule Two of the draft Invitation to Tender, that you think would be inappropriate to tender, and the reasons for that view;
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft Invitation to Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential

indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered;

- Any contractual constraints or patent protection that could restrict PHARMAC from awarding a Tender on a particular pharmaceutical;
- For Hospital pharmaceuticals, feedback on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event that a 1% Discretionary Variance Limit is considered clinically unacceptable; and
- feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance.

We seek comments on all sections of the draft Invitation to Tender. The draft Invitation to Tender is based on the format of the Invitation to Tender dated 23 December 2008 for community supply and/or hospital supply.

Alternative Commercial Proposals

PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit by **5pm, Friday 25 September 2009**.

An ACP, for example, may offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period.

Please note the following points with regard to ACPs for both the community and DHB Hospital markets:

- Proposals may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft Invitation to Tender;
- Proposals may seek PHARMAC's agreement to defer tendering or application of reference pricing as a result of a Tender award for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft Invitation to Tender;
- Proposals must not involve PHARMAC agreeing to award Sole Subsidised Supply in the community but may include the awarding of Hospital Supply Status for DHB Hospital pharmaceuticals;
- PHARMAC reserves the right:
 - not to accept any proposal; and/or
 - not to provide reasons for the acceptance or non-acceptance of any proposal; and/or
 - to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter; and
- PHARMAC may decide not to consider any proposal that is submitted after Friday 25 September 2009.

Tender Timelines

This year we are proposing to bring forward the tender timelines by one month, this would result in the final Invitation to Tender being released in late November, consequently the closing date for tender submissions would move forward to the last week of January. The proposed timeline is outlined in the following table:

Proposed Key Dates and Timeframes for the 2009/10 Tender:

Date	Event
August/September 2009	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
25 September 2009 (5pm)	Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC.
2 October 2009 (5pm)	Final date for all consultation to be received.
October 2009	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
October 2009	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
October/November 2009	Consultation and Board decisions on Alternative Commercial Proposals.
Late November 2009	Issuing of the 2009/10 Invitation to Tender.
Late January 2010	Invitation to Tender closes.
From February 2010	Board decisions on the first Tender winners announced.
30 June 2013	End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2009/10 Tender. Terms after the End Date may apply.

Depending on the feedback received via consultation, PHARMAC proposes to move forward the tender timelines by a further month in the 2010/11 Tender, with the approximate timeline outlined in the table below:

Proposed Key Dates and Timeframes for the 2010/11 Tender:

Date	Event
July/August 2010	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
August 2010	Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC.
September 2010	Final date for all consultation to be received.
September 2010	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September 2010	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2010	Consultation and Board decisions on Alternative Commercial Proposals.
Late October 2010	Issuing of the 2010/11 Invitation to Tender.
Late December 2010	Invitation to Tender closes.
From January 2011	Board decisions on the first Tender winners announced.

Since inception, PHARMAC's annual multi-product tender has generally been released at the end of December of each year with the closing date for tender submissions in late February or early March of the following year. Each year the Invitation to Tender includes a number of products coming off Sole Subsidised Supply at the end of June of the following year. Previous tender timelines have meant that April is the earliest month that the PHARMAC Board (or Chief Executive, under delegated authority) is able to make tender decisions that would involve a brand change. A number of suppliers have commented in the past that the existing timelines, on occasion, make it difficult for the incumbent (Sole Subsidised) supplier to manage its inventory while tender decisions are pending an announcement.

PHARMAC considers that moving forward the tender timelines by one month in the 2009/10 Tender and by a further month for the 2010/11 Tender may help to alleviate a number of stock management issues that have previously been experienced by suppliers during the transition period of a brand switch. Should this proposal be implemented, suppliers could be notified as early as January of tender decisions from the 2010/11 Tender.

Any feedback regarding the proposed tender timelines should be received by PHARMAC no later than **5pm, 2 October 2009**.

Draft Invitation to Tender

PHARMAC seeks feedback on the terms and conditions of the draft Invitation to Tender to be considered by the PHARMAC Board at its November 2009 meeting. Attached is the draft list of products to be tendered (Schedule Two).

A complete copy of the draft Invitation to Tender is available on our website (www.pharmac.govt.nz), including the terms of supply. PHARMAC proposes that, if a Tender Bid was accepted by the PHARMAC Board (or the Chief Executive under delegated authority), it would be subject to the terms and conditions of the draft Invitation to Tender.

The draft Invitation to Tender is still under development and may change before it is taken to the Board for approval and subsequently issued. PHARMAC is seeking feedback on the composition of the draft Invitation. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out any further drafts for consultation.

Any feedback regarding the draft Invitation should be received by PHARMAC no later than **5pm, 2 October 2009**. Late feedback may not be considered. Consultation feedback received by the due date will be presented to the PHARMAC Board for consideration before it makes its decision.

The draft Invitation to Tender comprises the following sections:

Schedule 1: Definitions and interpretation;

Schedule 2: The list of pharmaceuticals proposed to be tendered. Please note that the market data for the year ended 30 June 2009 provided in this Schedule has not yet been finalised; however finalised data would be captured in the final Invitation to Tender. The final list of pharmaceuticals would be released with the Invitation to Tender following Board approval (please note that the list may change following consultation, and that you may provide feedback on the inclusion of additional pharmaceuticals after the invitation to tender has been issued, and any such feedback would be considered by the Board (or Chief

Executive) before making a final decision on any Tender Bid provided that the feedback is given before the tender close date in early 2010);

- Schedule 3: Tender process (for both hospital and community Tenders);
- Schedule 4: Contract terms for Sole Subsidised Supply and/or Hospital Supply Status;
- Schedule 5: Additional contract terms for Sole Subsidised Supply;
- Schedule 6: Additional contract terms for Hospital Supply Status.

The main changes are:

Audit

PHARMAC proposes to amend clause 3 of Schedule 4 of the Invitation to Tender to include a provision that would provide an auditor authorised by PHARMAC, the access to the premises of any wholesaler or other distributors.

Withdrawal or suspension of Sole Supply Status and/or Hospital Supply Status

PHARMAC proposes to add a provision in clause 1.3 and clause 1.4 of Schedule 5; and clause 1.7 and clause 1.8 of Schedule 6 of the Invitation that would provide PHARMAC with the option to withdraw or suspend Sole Supply Status and/or Hospital Supply Status for other forms or strengths of the same chemical if PHARMAC has exercised its rights to withdraw or suspend Sole Supply Status under clause 1.3 or clause 1.4 of Schedule 5 and/or Hospital Supply Status under clause 1.7 and clause 1.8 of Schedule 6 of the Invitation to Tender.

Price

PHARMAC proposes to add a provision both in clause 3 of Schedule 5 and Schedule 6 of the Invitation to Tender that clarifies the expectation that the price offered by a supplier through the tender process would incorporate any costs incurred following the subsequent delisting of the product.

Electronic Tender (eTender) system

The final 2009/10 Invitation to Tender will be distributed via the eTender system and a test of supplier's email addresses will occur in November 2009. Please ensure that you respond by **5pm, 2 October 2009** with updated addresses if your email has changed.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 21 December 2007 (2007/08 Tender) and the Invitation to Tender dated 23 December 2008 (2008/09 Tender) prior to issuing the 2009/10 Invitation to Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in November 2009. Unresolved Tender Bids have not been included in the draft pharmaceutical list. PHARMAC seeks comments from suppliers that consider that any unresolved Tender Bid(s) should remain open for acceptance by **5pm, 2 October 2009**.

Reference Pricing

Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s).

The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios including:

- 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup; and/or
- 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others.

Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider any clinical considerations associated with such scenarios.

Products not currently listed on the Pharmaceutical Schedule

The following is a list of chemicals included in Schedule Two that are not currently listed on the Pharmaceutical Schedule:

- Abacavir Sulphate with Lamivudine and Zidovudine
- Bacillus Calmette-Guerin Vaccine
- Bisoprolol Fumarate
- Escitalopram
- Esomeprazole
- Gemfibrozil
- Glimepiride
- Ketamine Hydrochloride
- Nizatidine
- Pramipexole Hydrochloride
- Rabeprazole
- Risedronate Sodium
- Sertraline
- Topotecan

We note that funding of escitalopram, gemfibrozil, ketamine hydrochloride, pramipexole hydrochloride, rabeprazole, and sertraline have been considered by the Pharmacology and Therapeutic Advisory Committee (PTAC) or the relevant Subcommittee of PTAC; however further review, and the review of the remainder of the chemicals in the list above may be considered by PTAC and/or PTAC Subcommittee, after tender bids have been received.

Please note the decision to fund the chemicals listed above would largely depend on the pricing of Tender Bids against that of alternative chemicals already listed on the Pharmaceutical Schedule. We note that PHARMAC would be willing to support priority assessment from Medsafe to applications submitted as a result of the tender process where we consider it to be appropriate.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Abacavir Sulphate						
Oral liq 20 mg per ml	42,936	\$17,890	\$0.4167	C H	1%	
Tab 300 mg	35,393	\$270,167	\$7.6333	C H	1%	
Abacavir sulphate with lamivudine						
Tab 600 mg with lamivudine 300 mg	60,587	\$1,272,327	\$21.0000	C H	1%	
Abacavir Sulphate with Lamivudine and Zidovudine						
Tab 300 mg with lamivudine 150 mg, and zidovudine 300 mg				C		Not currently listed on the Pharmaceutical Schedule
Acebutolol						
Cap 100 mg	60,820	\$5,778	\$0.0950	C H	1%	
Cap 200 mg	130,884	\$20,863	\$0.1594	C H	1%	
Tab 400 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Alprazolam						
<u>Tab 250 mcg</u>	327,241	\$21,271	\$0.0650	C		
<u>Tab 500 mcg</u>	282,290	\$24,277	\$0.0860	C		
<u>Tab 1 mg</u>	84,739	\$13,304	\$0.1570	C		
Amiodarone Hydrochloride						
Inj 50 mg per ml, 3 ml	4,793	\$29,161	\$6.0840	C H	1%	
Amoxicillin						
<u>Cap 250 mg</u>	1,728,107	\$59,793	\$0.0346	C H	1%	
<u>Cap 500 mg</u>	10,097,812	\$550,331	\$0.0545	C H	1%	
Amsacrine						
Inj 75 mg				H PCT	1%	
Apomorphine Hydrochloride						
Inj 10 mg per ml	2,157	\$21,756	\$10.0860	C H	1%	
Arsenic trioxide						
Inj 10 mg				H PCT	1%	
Ascorbic Acid						
Eye drops 10%				H	1%	
Inj 500 mg per 5 ml				H	1%	
Tab 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 100 mg	1,329,567	\$45,870	\$0.0345	C H	1%	
Tab 250 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Aspirin						
Tab 100 mg	102,957,010	\$1,750,269	\$0.0170	C		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Aspirin					
Tab dispersible or soluble 300 mg	3,077,961	\$66,176	\$0.0215	C	
Atorvastatin					
Tab 10 mg	4,827,918	\$648,389	\$0.1343	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$2,878,089 for the year ended 30 June 2009
Tab 20 mg	6,791,393	\$1,329,076	\$0.1957	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$5,953,386 for the year ended 30 June 2009
Tab 40 mg	8,504,025	\$2,307,142	\$0.2713	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$10,440,546 for the year ended 30 June 2009
Tab 80 mg			\$0.5427	* + C	This was recently listed on the Pharmaceutical Schedule. A Special Authority for the Manufacturers Price currently exists
Azathioprine					
Inj 50 mg	30	\$1,390	\$46.3300	C H 1%	
Tab 50 mg	3,637,906	\$909,477	\$0.2500	C H 1%	
Bacillus Calmette-Guérin (BCG) Vaccine					
Inj containing equal to or greater than 500 million CFU				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement would be for non-vaccine use and may be subject to a Special Authority restriction
Beclomethasone Dipropionate					
Metered aqueous nasal spray, 50 mcg per dose	12,722,366	\$149,488	\$0.0118	C H 1%	
Metered aqueous nasal spray, 100 mcg per dose	47,280,695	\$581,553	\$0.0123	C H 1%	
Bisacodyl					
Tab 5 mg	1,551,489	\$39,485	\$0.0255	C H 1%	
Bisoprolol fumarate					
Tab 2.5 mg				C	Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority
Tab 5 mg				C	Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority
Tab 10 mg				C	Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Bleomycin sulphate							
Inj 15,000 iu					H 1%		
Budesonide							
Metered aqueous nasal spray, 50 mcg per dose	5,268,675	\$61,907	\$0.0118		C H 1%		
Metered aqueous nasal spray, 100 mcg per dose	30,304,478	\$395,473	\$0.0131		C H 1%		
Bumetanide							
Tab 1 mg	836,929	\$136,922	\$0.1636		C H 1%		
Bupivacaine Hydrochloride							
<u>Inf 0.125%, 100 ml theatre pack</u>					H 1%		
<u>Inf 0.125%, 200 ml theatre pack</u>					H 1%		
<u>Inf 0.25%, 100 ml theatre pack</u>					H 1%		
<u>Inj 0.5%, 8% glucose, 4 ml</u>	503	\$2,465	\$4.9000		C H 1%		
Busulphan							
Tab 2 mg	7,423	\$3,555	\$0.4789		C		
Caffeine Citrate							
Inj 10 mg per ml, 2.5 ml					H 1%		
Oral liq 10 mg per ml					H 1%		
Calcipotriol							
Crn 50 mcg per g (pack size 30 g or less)	1,419,618	\$821,817	\$0.5789		C H 1%	Volume is aggregated for all pack sizes of calcipotriol cream	
Crn 50 mcg per g (pack size greater than 30 g)	1,419,618	\$821,817	\$0.5789		C H 1%	Volume is aggregated for all pack sizes of calcipotriol cream	
Oint 50 mcg per g (pack size 30 g or less)	1,507,289	\$1,043,044	\$0.6920		C H 1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Oint 50 mcg per g (pack size greater than 30 g)	1,507,289	\$1,043,044	\$0.6920		C H 1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Soln 50 mcg per ml (pack size 30 ml or less)	313,503	\$217,153	\$0.6927		C H 1%	Volume is aggregated for all pack sizes of calcipotriol solution	
Soln 50 mcg per ml (pack size greater than 30 ml)	313,503	\$217,153	\$0.6927		C H 1%	Volume is aggregated for all pack sizes of calcipotriol solution	
Captopril							
Oral liq 5 mg per ml	85,273	\$45,814	\$0.5373		C H 1%		
<u>Tab 12.5 mg</u>	505,495	\$10,514	\$0.0208		C H 1%		
<u>Tab 25 mg</u>	830,687	\$22,262	\$0.0268		C H 1%		
<u>Tab 50 mg</u>	637,696	\$24,232	\$0.0380		C H 1%		
Carmustine							
Inj 100 mg					H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Cefaclor Monohydrate						
<u>Cap 250 mg</u>	3,894,014	\$1,125,370	\$0.2890	C H	1%	
<u>Grans for oral liq 125 mg per 5 ml</u>	10,276,124	\$402,824	\$0.0392	C H	1%	
Cetomacrogol						
<u>Crm BP</u>	12,146,581	\$85,026	\$0.0070	C		
Chlorambucil						
Tab 2 mg	85,751	\$76,661	\$0.8940	C H	1%	
Cholecalciferol						
Tab 1.25 mg (50,000 iu)	1,176,907	\$1,015,082	\$0.8625	C H	1%	
Cilazapril						
Tab 0.5 mg	14,646,190	\$1,074,054	\$0.0733	C		
Tab 2.5 mg	17,316,642	\$2,534,002	\$0.1463	C		
Tab 5 mg	16,520,567	\$3,546,415	\$0.2147	C		
Cilazapril with Hydrochlorothiazide						
Tab 5 mg with Hydrochlorothiazide 12.5 mg	17,897,458	\$4,026,928	\$0.2250	C		
Ciprofloxacin						
Inj 2 mg per ml, 100 ml				H	1%	
Cisplatin						
Inj 10 mg				H PCT	1%	Not currently listed on the Pharmaceutical Schedule
Inj 50 mg				H PCT	1%	
Inj 100 mg				H PCT	1%	
Cladribine						
Inj 1 mg per ml, 10 ml				H PCT	1%	
Inj 2 mg per ml, 5 ml				H PCT	1%	
Clarithromycin						
<u>Tab 250 mg</u>	86,986	\$48,153	\$0.5536	C H	1%	
Clindamycin						
Inj phosphate 150 mg per ml, 4 ml	1,141	\$22,192	\$19.4500	C H	1%	
Clopidogrel						
Tab 75 mg	1,820,845	\$2,276,056	\$1.2500	C H	1%	
Clotrimazole						
Pessaries 100 mg with applicator(s)				C		Not currently listed on the Pharmaceutical Schedule
Pessaries 500 mg with applicator				C		Not currently listed on the Pharmaceutical Schedule
<u>Vaginal crm 1% with applicators</u>	1,914,684	\$79,323	\$0.0414	C H	1%	
<u>Vaginal crm 2% with applicators</u>	1,086,351	\$149,373	\$0.1375	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Coal Tar						
Soln BP			\$0.0730		C	There are two different subsidies, unit subsidy reflects the subsidy of the fully funded product. Market information unavailable
Codeine Phosphate						
<u>Tab 15 mg</u>	4,033,866	\$221,863	\$0.0550		C H	1%
<u>Tab 30 mg</u>	18,209,124	\$1,547,776	\$0.0850		C H	1%
<u>Tab 60 mg</u>	1,785,587	\$330,334	\$0.1850		C H	1%
Colchicine						
<u>Tab 500 mcg - 600 mcg</u>	3,618,128	\$347,340	\$0.0960		C H	1%
Colistin Sulphomethate						
<u>Inj 150 mg</u>	7,452	\$484,380	\$65.0000		C H	1%
Compound Electrolytes						
<u>Powder for soln for oral use</u>	791,686	\$226,422	\$0.2860		C	
Cyclophosphamide						
<u>Tab 50 mg</u>	88,044	\$45,272	\$0.5142		C H	1%
Cyclosporin A						
Cap 25 mg	1,032,971	\$1,756,051	\$1.7000		C H	1%
Cap 50 mg	280,201	\$948,985	\$3.3868		C H	1%
Cap 100 mg	488,652	\$3,310,031	\$6.7738		C H	1%
Oral liq 100 mg per ml	16,189	\$122,188	\$7.5476		C H	1%
Cytarabine						
Inj 100 mg			\$16.0000		C H	1%
Inj 500 mg			\$19.0720		C H	1%
Inj 1 g			\$42.6500		C H	1%
Inj 2 g					H	1%
Dacarbazine						
Inj 50 mg					H PCT	1%
Inj 200 mg					H PCT	1%
Dactinomycin (actinomycin D)						
Inj 0.5 mg					H PCT	1%
Daunorubicin						
Inj 20 mg					H PCT	1%
Desferrioxamine Mesylate						
<u>Inj 500 mg</u>	22,093	\$218,721	\$9.9000		C H	1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Dexamethasone Sodium Phosphate						
Inj 4 mg per ml, 1 ml	31,713	\$136,366	\$4.3000	C H	1%	
Inj 4 mg per ml, 2 ml	76,573	\$474,753	\$6.2000	C H	1%	
Dexamphetamine Sulphate						
Tab 5 mg	636,761	\$108,249	\$0.1700	C H	1%	
Dextrose with Electrolytes						
<u>Soln with electrolytes</u>	90,789,984	\$604,661	\$0.0067	C		Sole supply would only be awarded to a range of flavours
Dobutamine						
Inj 12.5 mg per ml, 20 ml				H	1%	
Domperidone						
Tab 10 mg	6,579,837	\$256,614	\$0.0390	C		A Special Authority for full subsidy currently exists. The Special Authority would be removed should a tender be awarded
Doxazosin Mesylate						
<u>Tab 2 mg</u>	9,601,118	\$438,771	\$0.0457	C H	1%	
<u>Tab 4 mg</u>	8,384,024	\$507,401	\$0.0605	C H	1%	
Emtricitabine						
Cap 200 mg	124,667	\$1,276,590	\$10.2400	C H	1%	
Ephedrine Sulphate						
Inj 30 mg per ml, 1 ml				H	1%	
Ergometrine Maleate						
Inj 500 mcg per ml, 1 ml	1,023	\$2,373	\$2.3200	C H	1%	
Ergotamine Tartrate with Caffeine						
Tab 1 mg with caffeine 100 mg	423,371	\$131,245	\$0.3100	C H	1%	
Escitalopram						
Tab 10 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 20 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Esomeprazole						
Inj 40 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 20 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 40 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Etoposide						
Cap 50 mg	7,910	\$134,759	\$17.0365	C H	1%	
Cap 100 mg	554	\$18,876	\$34.0730	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Etoposide Phosphate							
Inj 100 mg (of etoposide base)					H PCT 1%		
Exemestane							
Tab 25 mg	134,667	\$785,558	\$5.8333		C H 1%		
Famotidine							
Tab 20 mg	709,966	\$23,003	\$0.0324		C H 1%		
Tab 40 mg	621,078	\$28,197	\$0.0454		C H 1%		
Ferrous Salts							
<u>Oral liq</u>	3,817,372	\$78,638	\$0.0206		C H 1%		
Tab (short-acting)					C H 1%	Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required	
Tab (long-acting)					C H 1%	Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required	
Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine							
<u>Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g</u>	2,353,042	\$498,061	\$0.2117		C H 1%	All corticosteroids ointments in the antihemorrhoidals group are considered as one Tender Item	
<u>Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg</u>	730,228	\$161,867	\$0.2217		C H 1%	All corticosteroids suppositories in the antihemorrhoidals group are considered as one Tender Item	
Fluorouracil Sodium							
<u>Inj 25 mg per ml, 100 ml</u>					H PCT 1%		
<u>Inj 50 mg per ml, 10 ml</u>					H PCT 1%		
<u>Inj 50 mg per ml, 20 ml</u>					H PCT 1%		
<u>Inj 50 mg per ml, 50 ml</u>					H PCT 1%		
<u>Inj 50 mg per ml, 100 ml</u>					H PCT 1%		
Fluoxetine Hydrochloride							
<u>Cap 20 mg</u>	21,564,650	\$1,051,876	\$0.0488		C H 1%		
<u>Tab dispersible 20 mg, scored</u>	854,866	\$156,725	\$0.1833		C H 1%		
Flutamide							
Tab 250 mg	453,951	\$179,311	\$0.3950		C H 1%		
Furosemide							
Inj 10 mg per ml, 2 ml	19,591	\$11,559	\$0.5900		C H 1%		
Inj 20 mg per ml, 2 ml					C H 1%	Not currently listed on the Pharmaceutical Schedule	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Fusidic Acid						
<u>Crm 2 %</u>	1,466,886	\$386,280	\$0.2633	C H	1%	
<u>Oint 2 %</u>	1,002,501	\$263,992	\$0.2633	C H	1%	
Gemcitabine Hydrochloride						
<u>Inj 200 mg</u>				H PCT	1%	
<u>Inj 1 g</u>				H PCT	1%	
Gemfibrozil						
Tab 300 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered
Tab 600 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered
Gentamicin Sulphate						
Inj 10 mg per ml, 1 ml			\$1.7120	C H	1%	Market information unavailable
Glimepiride						
Tab 1 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 2 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 3 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 4 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Glycerol						
Liq BP			\$0.0124	C H	1%	Market information unavailable
Suppos 3 g or less	56,472	\$14,683	\$0.2600	C H	1%	
Suppos greater than 3 g	263,122	\$65,781	\$0.2500	C H	1%	
Glyceryl Trinitrate						
Inj 5 mg per ml, 1 ml				H	1%	
Inj 5 mg per ml, 10 ml				H	1%	
Haloperidol						
Inj 5 mg per ml, 1 ml	39,565	\$67,419	\$1.7040	C H	1%	
<u>Oral liq 2 mg per ml</u>	65,301	\$11,793	\$0.1806	C H	1%	
<u>Tab 500 mcg</u>	1,232,826	\$60,778	\$0.0493	C H	1%	
<u>Tab 1.5 mg</u>	258,263	\$19,241	\$0.0745	C H	1%	
<u>Tab 5 mg</u>	262,642	\$61,695	\$0.2349	C H	1%	
Hydralazine						
Inj 20 mg per ml, 1 ml	52	\$269	\$5.1800	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Hydrocortisone						
Inj 50 mg per ml, 2 ml	6,999	\$26,036	\$3.7200	C H	1%	
Hydrocortisone Butyrate						
<u>Scalp lotn 0.1%</u>	3,642,476	\$273,914	\$0.0752	C H	1%	
Hydrocortisone with Cinchocaine						
Oint 5 mg with cinchocaine hydrochloride 5 mg per g				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihæmmorrhoidals group are considered as one Tender Item
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihæmmorrhoidals group are considered as one Tender Item
Hydrocortisone with Lignocaine, Aluminium and Zinc						
Oint 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihæmmorrhoidals group are considered as one Tender Item
Suppos 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihæmmorrhoidals group are considered as one Tender Item
Hydrocortisone with Natamycin and Neomycin						
Crn 1% with natamycin 1% and neomycin sulphate 0.5%	1,793,319	\$526,040	\$0.2933	C		
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	817,977	\$239,940	\$0.2933	C		
Ibuprofen						
<u>Oral liq 100 mg per 5 ml</u>	27,842,543	\$485,852	\$0.0175	C H	1%	
Imatinib Mesylate						
Tab 100 mg	395,319	\$15,812,760	\$40.0000	+ C H	1%	Tender agreement may be subject to a Special Authority restriction
Imipramine Hydrochloride						
Tab 10 mg	496,156	\$54,379	\$0.1096	C H	1%	
Tab 25 mg	1,579,879	\$278,059	\$0.1760	C H	1%	
Indomethacin						
Cap 25 mg	291,147	\$17,178	\$0.0590	C H	1%	
Cap 50 mg	782,475	\$54,382	\$0.0695	C H	1%	
Cap long-acting 75 mg	589,424	\$78,393	\$0.1330	C H	1%	
Suppos 100 mg	39,921	\$19,295	\$0.4833	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Ipratropium Bromide						
<u>Aqueous nasal spray, 0.03%</u>	784,748	\$331,164	\$0.4220	C		
<u>Nebuliser soln, 250 mcg per 1 ml</u>	78,380	\$16,852	\$0.2150	C H	1%	
<u>Nebuliser soln, 500 mcg per 2 ml</u>	412,284	\$108,225	\$0.2625	C H	1%	
Isoniazid						
Tab 100 mg	271,862	\$55,732	\$0.2050	C		
Itraconazole						
<u>Cap 100 mg</u>	581,374	\$918,571	\$1.5800	C H	1%	
Ketamine Hydrochloride						
Inj 10 mg per ml				C H	1%	Not currently listed in the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 50 mg per ml				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 100 mg per ml				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Lactulose						
<u>Oral liq 10 g per 15 ml</u>	182,005,412	\$1,210,336	\$0.0067	C H	1%	
Lamivudine						
Oral liq 5 mg per ml	6,220	\$2,333	\$0.3750	C		
Oral liq 10 mg per ml	36,198	\$15,083	\$0.4167	C		
Tab 100 mg	327,610	\$1,673,151	\$5.1071	C		
Tab 150 mg	32,249	\$165,115	\$5.1200	C		
Levodopa with Benserazide						
Cap 50 mg with benserazide 12.5 mg	1,036,487	\$82,919	\$0.0800	C H	1%	
Cap 100 mg with benserazide 25 mg	1,186,884	\$148,361	\$0.1250	C H	1%	
Cap 200 mg with benserazide 50 mg	176,281	\$44,070	\$0.2500	C H	1%	
Cap long-acting 100 mg with benserazide 25 mg	567,392	\$96,457	\$0.1700	C H	1%	
Tab dispersible 50 mg with benserazide 12.5 mg	477,398	\$47,740	\$0.1000	C H	1%	
Levonorgestrel						
Tab 30 mcg	836,896	\$65,955	\$0.0788	C		
Tab 750 mcg - 1.5 mg	56,343	\$704,288	\$12.5000	C		Bids would be accepted for a tablet within this strength range
Lignocaine						
Viscous solution 2%				C H	1%	Not currently listed on the Pharmaceutical Schedule

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Lignocaine Hydrochloride							
<u>Inj 0.5%, 5 ml</u>	11,967	\$10,555	\$0.8820	C H	1%		
<u>Pump spray 10%, 50 ml CFC-free</u>				H	1%		
<u>Inj 1%, 5 ml</u>	37,078	\$31,146	\$0.8400	C			
<u>Inj 1%, 20 ml</u>	1,783	\$8,380	\$4.7000	C			
Lignocaine Hydrochloride with Adrenaline							
<u>Inj 1% with 1:100,000 of adrenaline, 5 ml</u>				H	1%		
<u>Inj 1% with 1:200,000 of adrenaline, 20 ml</u>				H	1%		
<u>Inj 2% with 1:200,000 of adrenaline, 20 ml</u>				H	1%		
Lignocaine with Prilocaine Hydrochloride							
Crn 2.5% with prilocaine hydrochloride 2.5% 5 g	577	\$4,731	\$8.2000	C H	1%		
Crn 2.5% with prilocaine hydrochloride 2.5% 30 g	1,335	\$1,825	\$1.3667	C H	1%		
Lithium carbonate							
Tab long-acting 400 mg	1,228,213	\$197,128	\$0.1605	C			
Lomustine							
Cap 10 mg				H PCT	1%		
Cap 40 mg				H PCT	1%		
Loperamide Hydrochloride							
<u>Tab 2 mg</u>	6,069,760	\$174,506	\$0.0288	C		Capsule form would be considered	
Lopinavir with ritonavir							
Oral liq 80 mg with ritonavir 20 mg per ml	17,838	\$43,703	\$2.4500	+ C H	1%	Tender agreement may be subject to a Special Authority restriction	
Tab 200 mg with ritonavir 50 mg	217,934	\$1,334,846	\$6.1250	+ C H	1%	Tender agreement may be subject to a Special Authority restriction	
Loratadine							
<u>Oral liq 1 mg per ml</u>	8,544,371	\$311,870	\$0.0365	C H	1%		
<u>Tab 10 mg</u>	14,238,914	\$509,753	\$0.0358	C H	1%		
Lorazepam							
Tab 1 mg	4,504,048	\$113,142	\$0.0251	C H	1%		
Tab 2.5 mg	256,352	\$10,562	\$0.0412	C H	1%		
Magnesium Sulphate							
Paste (pack size 100 g or less)	245,281	\$9,137	\$0.0373	C H	1%		
Malathion							
<u>Liq 0.5%</u>	9,322,516	\$232,597	\$0.0250	C			
<u>Shampoo 1%</u>	564,454	\$53,247	\$0.0943	C			

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Medroxyprogesterone Acetate						
<u>Tab 2.5 mg</u>	221,643	\$15,293	\$0.0690	C H	1%	
<u>Tab 5 mg</u>	519,805	\$71,473	\$0.1375	C H	1%	
<u>Tab 10 mg</u>	864,393	\$218,115	\$0.2523	C H	1%	
<u>Tab 100 mg</u>	44,252	\$46,137	\$1.0426	C H	1%	
<u>Tab 200 mg</u>	1,192	\$3,102	\$2.6020	C H	1%	
Melphalan						
Inj 50 mg					H PCT 1%	
Tab 2 mg	14,585	\$18,266	\$1.2524	C H	1%	
Menthol						
Crystals			\$0.2960	C		Market information unavailable
Mercaptopurine						
Tab 50 mg	212,009	\$399,086	\$1.8824	C H	1%	
Mesalazine						
Tab 400 mg	2,197,126	\$1,087,577	\$0.4950	C H	1%	
Mesna						
Tab 400 mg					H PCT 1%	
Tab 600 mg					H PCT 1%	
<u>Inj 100 mg per ml, 4 ml</u>					H PCT 1%	
<u>Inj 100 mg per ml, 10 ml</u>					H PCT 1%	
Methadone Hydrochloride						
Inj 10 mg per ml, 1 ml	35,728	\$217,941	\$6.1000	C H	1%	
<u>Tab 5 mg</u>	1,975,773	\$414,912	\$0.2100	C H	1%	
Methotrexate						
Inj 25 mg per ml, 2 ml	6,882	\$63,452	\$9.2200	C H	1%	
Inj 25 mg per ml, 20 ml	23	\$1,846	\$80.2500	C H	1%	
Inj 10 mg per ml, 0.75 ml prefilled syringe				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 10 mg per ml, 1 ml prefilled syringe				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 10 mg per ml, 1.5 ml prefilled syringe				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Methotrexate						
Inj 10 mg per ml, 2 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction	
Inj 10 mg per ml, 2.5 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction	
Methyl Hydroxybenzoate						
Powder			\$0.4000	C	Market information unavailable	
Methylcellulose						
Powder			\$0.1400	C	Market information unavailable	
Metoclopramide Hydrochloride						
Oral liq 5 mg per 5 ml			\$0.0000	C H 1%	Not currently listed on the Pharmaceutical Schedule	
Metronidazole						
Tab 200 mg	288,833	\$27,439	\$0.0950	C		
Tab 400 mg	1,103,006	\$193,026	\$0.1750	C		
Miconazole						
Oral gel 20 mg per g	660,769	\$143,717	\$0.2175	C H 1%		
Mitomycin C						
Inj 2 mg				H PCT 1%		
Inj 10 mg				H PCT 1%		
Mitozantrone						
Inj 2 mg per ml, 5 ml				H PCT 1%		
Inj 2 mg per ml, 10 ml				H PCT 1%		
Morphine Sulphate						
Cap long-acting 10 mg	2,852,145	\$513,386	\$0.1800	C H 1%		
Cap long-acting 30 mg	1,052,319	\$277,812	\$0.2640	C H 1%		
Cap long-acting 60 mg	408,428	\$294,068	\$0.7200	C H 1%		
Cap long-acting 100 mg	304,539	\$239,063	\$0.7850	C H 1%		
Cap long-acting 200 mg	39,285	\$66,785	\$1.7000	C H 1%		
Inj 5 mg per ml, 1 ml	25,813	\$26,691	\$1.0340	C H 1%		
Inj 15 mg per ml, 1 ml	11,355	\$10,674	\$0.9400	C H 1%		
Tab long-acting 10 mg	728,273	\$131,089	\$0.1800	C H 1%		
Tab long-acting 30 mg	356,403	\$128,305	\$0.3600	C H 1%		
Tab long-acting 60 mg	175,275	\$126,198	\$0.7200	C H 1%		
Tab long-acting 100 mg	244,268	\$207,628	\$0.8500	C H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Morphine Sulphate						
Tab long-acting 200 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Morphine Tartrate						
Inj 80 mg per ml, 1.5 ml	26,690	\$107,828	\$4.0400	C H	1%	
Inj 80 mg per ml, 5 ml	2,560	\$34,493	\$13.4740	C H	1%	
Naloxone Hydrochloride						
Inj 400 mcg per ml, 1 ml	11,165	\$73,689	\$6.6000	C H	1%	Min-I-Jet would not be DV Pharmaceutical
Naltrexone hydrochloride						
<u>Tab 50 mg</u>	84,773	\$508,638	\$6.0000	C H	1%	
Naproxen						
Tab long-acting 750 mg	893,953	\$178,791	\$0.2000	C H	1%	
Tab long-acting 1,000 mg	813,534	\$189,825	\$0.2333	C H	1%	
Naproxen Sodium						
<u>Tab 275 mg</u>	1,890,518	\$94,526	\$0.0500	C H	1%	
Tab 550 mg	4,289,670	\$549,078	\$0.1280	C H	1%	
Neostigmine						
<u>Inj 2.5 mg per ml, 1 ml</u>	27,169	\$11,031	\$0.4060	C H	1%	
Nizatidine						
Cap 150 mg				C	1%	Not currently listed on the Pharmaceutical Schedule
Cap 300 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Nystatin						
<u>Cap 500,000 u</u>	230,477	\$53,655	\$0.2328	C H	1%	
<u>Tab 500,000 u</u>	76,029	\$14,598	\$0.1920	C H	1%	
Octreotide (somatostatin analogue)						
LAR inj 10 mg	226	\$400,585	\$1,772.5000	C H	1%	
LAR inj 20 mg	953	\$2,247,889	\$2,358.7500	C H	1%	
LAR inj 30 mg	744	\$2,195,730	\$2,951.2500	C H	1%	
Olanzapine						
Oradispersible 5 mg				+ H	5%	
Orodispersible 10 mg				+ H	5%	
Tab 2.5 mg				+ H	5%	
Tab 5 mg				+ H	5%	
Tab 10 mg				+ H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Ondansetron						
<u>Tab 4 mg</u>	30,087	\$51,689	\$1.7180	C H	1%	
<u>Tab 8 mg</u>	112,932	\$191,363	\$1.6945	C H	1%	
<u>Tab disp 4 mg</u>	15,985	\$27,462	\$1.7180	C H	1%	
<u>Tab disp 8 mg</u>	6,477	\$13,233	\$2.0430	C H	1%	
Orphenadrine Citrate						
Tab 100 mg	1,436,969	\$266,414	\$0.1854	C H	1%	
Oxybutynin						
<u>Oral liq 5 mg per 5 ml</u>	612,575	\$65,272	\$0.1066	C H	1%	
<u>Tab 5 mg</u>	5,876,883	\$526,451	\$0.0896	C H	1%	
Oxycodone Hydrochloride						
Cap 5 mg	1,039,973	\$147,156	\$0.1415	+ C H	1%	
Cap 10 mg	695,650	\$194,086	\$0.2790	+ C H	1%	
Cap 20 mg	372,631	\$182,030	\$0.4885	+ C H	1%	
Inj 10 mg per ml, 1 ml	22,764	\$65,560	\$2.8800	C H	1%	
Inj 10 mg per ml, 2 ml	21,769	\$125,389	\$5.7600	C H	1%	
<u>Oral liq 5 mg per 5 ml</u>	715,606	\$32,059	\$0.0448	C H	1%	
Tab controlled-release 5 mg	640,801	\$240,621	\$0.3755	+ C H	1%	
Tab controlled-release 10 mg	1,415,423	\$788,391	\$0.5570	+ C H	1%	
Tab controlled-release 20 mg	879,265	\$832,224	\$0.9465	+ C H	1%	
Tab controlled-release 40 mg	303,822	\$505,712	\$1.6645	+ C H	1%	
Tab controlled-release 80 mg	139,168	\$403,796	\$2.9015	+ C H	1%	
Pantoprazole						
<u>Inj 40 mg</u>			\$8.7500	C H	1%	
<u>Tab 20 mg</u>	4,351,274	\$348,102	\$0.0800	C H	1%	
<u>Tab 40 mg</u>	7,307,110	\$876,853	\$0.1200	C H	1%	
Paracetamol						
Suppos 125 mg	66,981	\$25,084	\$0.3745	C H	1%	
Suppos 250 mg	43,621	\$31,407	\$0.7200	C H	1%	
Suppos 500 mg	129,304	\$53,015	\$0.4100	C H	1%	
Paraffin Liquid with Soft White Paraffin						
<u>Eye oint with soft white paraffin</u>	101,341	\$105,105	\$1.0371	C		
Paraldehyde						
Inj 5 ml	219	\$65,700	\$300.0000	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Paroxetine hydrochloride						
Tab 20 mg	13,646,015	\$2,683,716	\$0.1967	C H	1%	
Pentostatin (deoxycoformycin)						
Inj 10 mg				H PCT	1%	
Pethidine Hydrochloride						
Inj 50 mg per ml, 1 ml	23,247	\$24,177	\$1.0400	C H	1%	
Inj 50 mg per ml, 1.5 ml			\$0.8700	C H	1%	
Inj 50 mg per ml, 2 ml	70,243	\$77,267	\$1.1000	C H	1%	
Tab 50 mg	278,785	\$83,636	\$0.3000	C		
Tab 100 mg	105,727	\$42,291	\$0.4000	C		
Phenobarbitone						
Tab 15 mg	84,843	\$4,018	\$0.0474	C H	1%	
Tab 30 mg	781,463	\$38,432	\$0.0492	C H	1%	
Phenoxymethylpenicillin (Penicillin V)						
<u>Cap 250 mg</u>	555,005	\$47,619	\$0.0858	C H	1%	
<u>Cap 500 mg</u>	2,342,365	\$381,805	\$0.1630	C H	1%	
<u>Grans for oral liq benzathine 125 mg per 5 ml</u>	2,061,408	\$34,632	\$0.0168	C H	1%	
<u>Grans for oral liq benzathine 250 mg per 5 ml</u>	4,896,391	\$89,114	\$0.0182	C H	1%	
Piperacillin Sodium with Tazobactam Sodium						
Inj 4 g with tazobactam sodium 500 mg				H	1%	
Piroxicam						
Tab dispersible 10 mg	41,511	\$2,698	\$0.0650	C H	1%	
Tab dispersible 20 mg	389,484	\$21,422	\$0.0550	C H	1%	
Pramipexole Hydrochloride						
Tab 0.125 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 0.250 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 1 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 1.5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Prazosin Hydrochloride						
<u>Tab 1 mg</u>	401,233	\$22,188	\$0.0553	C H	1%	
<u>Tab 2 mg</u>	407,528	\$28,527	\$0.0700	C H	1%	
<u>Tab 5 mg</u>	267,577	\$31,307	\$0.1170	C H	1%	
Prilocaine Hydrochloride						
<u>Inj, 0.5%, 50 ml</u>				H	1%	
<u>Inj, 2%, 5 ml</u>				H	1%	
Procarbazine Hydrochloride						
Cap 50 mg				H PCT	1%	
Propylene Glycol						
Liq			\$0.0354	C		Market information unavailable
Pyridoxine Hydrochloride						
Tab 25 mg	643,577	\$21,882	\$0.0340	C H	1%	
Rabeprazole						
Tab 10 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 20 mg			\$0.0000	C H	1%	Not currently listed on the Pharmaceutical Schedule
Rifabutin						
<u>Cap 150 mg</u>	10,269	\$72,975	\$7.1063	C H	1%	
Risedronate sodium						
Tab 5 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 30 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 35 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 150 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Rizatriptan benzoate						
Wafer 10 mg	130,467	\$1,101,141	\$8.4400	+ C H	1%	
Ropinirole Hydrochloride						
<u>Tab 0.25 mg</u>	308,433	\$29,007	\$0.0940	C H	1%	
<u>Tab 1 mg</u>	710,596	\$341,086	\$0.4800	C H	1%	
<u>Tab 2 mg</u>	375,380	\$271,346	\$0.7229	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Ropinirole Hydrochloride						
<u>Tab 5 mg</u>	75,658	\$81,062	\$1.0714	C H	1%	
Salbutamol						
<u>Oral liq 2 mg per 5 ml</u>	1,019,202	\$15,288	\$0.0150	C H	1%	
Salicylic Acid						
Powder			\$0.0755	C		Market information unavailable
Sertraline						
Tab 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 100 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Sirolimus						
Oral liq 1 mg per ml	2,839	\$23,081	\$8.1300	C H	1%	
Tab 1 mg	83,240	\$676,741	\$8.1300	C H	1%	
Tab 2 mg	3,572	\$58,081	\$16.2600	C H	1%	
Sodium Bicarbonate						
Powder BP			\$0.0196	C H	1%	Market information unavailable
Sodium Chloride						
Inj 0.9%, 5 ml	133,175	\$30,630	\$0.2300	C H	1%	
Inj 0.9%, 10 ml	543,388	\$124,979	\$0.2300	C H	1%	
Inj 0.9%, 20 ml	102,212	\$40,169	\$0.3930	C H	1%	
Inj 23.4%, 20 ml	3,735	\$19,796	\$5.3000	C H	1%	
Sodium Citrate with Sodium Lauryl Sulphoacetate						
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	339,630	\$206,597	\$0.6083	C H	1%	
Sodium Citro-Tartrate						
<u>Grans effervescent 4 g sachets</u>	1,372,285	\$134,778	\$0.0982	C		
Sodium Cromoglycate						
Eye drops 2%	494,850	\$195,466	\$0.3950	C		
Sodium Fluorescein						
Inj 100 mg per ml				H	1%	
Spironolactone						
Tab 25 mg	5,328,826	\$452,950	\$0.0850	C H	1%	
Tab 100 mg	1,295,640	\$281,154	\$0.2170	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Sulphur						
Precipitated			\$0.0650	C		Market information unavailable
Suxamethonium						
<u>Inj 50 mg per ml, 2 ml</u>				H	1%	
Tacrolimus						
Cap 0.5 mg	135,044	\$288,994	\$2.1400	C H	1%	
Cap 1 mg	1,069,733	\$4,578,457	\$4.2800	C H	1%	
Cap 5 mg	64,144	\$1,372,682	\$21.4000	C H	1%	
Temozolomide						
Cap 5 mg	3,957	\$39,570	\$10.0000	C H	1%	
Cap 20 mg	8,369	\$284,546	\$34.0000	C H	1%	
Cap 100 mg	7,341	\$1,233,288	\$168.0000	C H	1%	
Cap 250 mg	382	\$160,440	\$420.0000	C H	1%	
Teniposide						
Inj 10 mg per ml, 5 ml				H PCT	1%	
Tenoxicam						
Tab 20 mg	1,763,099	\$418,736	\$0.2375	C H	1%	
Terazosin Hydrochloride						
Tab 1 mg			\$0.0893	C		This was recently listed on the Pharmaceutical Schedule
<u>Tab 2 mg</u>	3,816,567	\$177,852	\$0.0466	C		
<u>Tab 5 mg</u>	2,895,729	\$167,952	\$0.0580	C		
Testosterone						
Transdermal patch 2.5 mg per day	105,858	\$141,140	\$1.3333	C H	1%	
Tetrabenazine						
Tab 25 mg	116,287	\$252,301	\$2.1696	C H	1%	
Thalidomide						
Cap 50 mg				H PCT	1%	
Thioguanine						
Tab 40 mg	6,434	\$25,005	\$3.8864	C H	1%	
Thiotepa						
Inj 15 mg				H PCT	1%	
Tolcapone						
Tab 100 mg	116,011	\$149,364	\$1.2875	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Topotecan					
Inj 1 mg				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 4 mg				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tretinoin					
Cap 10 mg				H PCT 1%	
Venlafaxine					
Tab immediate-release 12.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 25 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 37.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 50 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 75 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 100 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Vincristine Sulphate					
Inj 1 mg per ml, 1 ml				H PCT 1%	
Inj 1 mg per ml, 2 ml				H PCT 1%	
Vitamin B Complex (BPC, strong)					
Tab	2,369,926	\$57,352	\$0.0242	C	
Vitamins (BPC cap strength)					
Tab	24,790,242	\$366,896	\$0.0148	C	
Wool Fat with Mineral Oil					
Lotn hydrous 3% with mineral oil	10,719,597	\$60,030	\$0.0056	* C	
Zidovudine (AZT)					
Cap 100 mg	47,957	\$139,075	\$2.9000	+ C H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Zidovudine (AZT)						
Oral liq 10 mg per ml	60,246	\$17,471	\$0.2900	+ C H	1%	
Zinc						
Crm BP	220,121	\$2,884	\$0.0131	* C		
Zoledronic Acid						
Inj 4 mg				H	1%	
Inj 5 mg				H	1%	